Brief: Arcutis Biotherapeutics Says Zoryve Topical Foam, 0.3% Clears Seborrheic Dermatitis

Arcutis Biotherapeutics

14/01/2024 10:40

Jan 14 (Reuters) - Arcutis Biotherapeutics Inc  ARQT.O :
    * ZORYVE TOPICAL FOAM, 0.3% CLEARS SEBORRHEIC DERMATITIS IN
INDIVIDUALS WHO PREVIOUSLY REPORTED INADEQUATE RESPONSE TO
TOPICAL STEROIDS
    * ZORYVE FOAM PROVIDED RAPID AND SIGNIFICANT IMPROVEMENT IN
QUALITY OF LIFE SCORES IN PATIENTS 17 YEARS AND OLDER
    * ZORYVE FOAM WAS WELL-TOLERATED WITH A FAVORABLE SAFETY AND
TOLERABILITY PROFILE
    * INCIDENCE OF TREATMENT EMERGENT ADVERSE EVENTS (TEAES) WAS
LOW
AND SIMILAR BETWEEN ACTIVE TREATMENT AND VEHICLE
    * THERE WERE NO TREATMENT-RELATED SERIOUS ADVERSE EVENTS
(SAES)

Source text for Eikon:  ID:nGNX58xVsV 
Further company coverage:  ARQT.O 

 ((Reuters.Briefs@thomsonreuters.com;))